|
Delayed
Nasdaq
04:00:00 2025-08-14 pm EDT
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.87B 2.69B 2.45B 4.61B 318B 4.67B 31.53B 12.36B 159B 12.47B 12.2B 529B | P/E 2023 |
-317x | P/E 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 3B 2.82B 2.57B 4.82B 332B 4.89B 33.01B 12.94B 167B 13.06B 12.77B 554B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 25-09-30 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 25-07-29 | Amedisys: Q2 Earnings Snapshot | AQ |
| 25-07-29 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 25-07-29 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 25-04-23 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 3 years | 82.15 |  | 101.02 |
| 5 years | 69.36 | | 188.88 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 2017-10-05 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 2016-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/14/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 8/14/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 8/14/25 | Issuer sale | Chief Executive Officer | 520,347 | 1.5886% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 1.93B 1.81B 1.65B 3.1B 214B 3.15B 21.23B 8.32B 107B 8.4B 8.21B 356B | 2.35B 2.03B 1.9B 1.73B 3.26B 225B 3.3B 22.3B 8.74B 112B 8.82B 8.63B 374B |
| Net income | -9.75M -8.41M -7.89M -7.19M -13.52M -932M -13.71M -92.54M -36.26M -467M -36.59M -35.8M -1.55B | 43.23M 37.32M 35.01M 31.89M 59.96M 4.13B 60.8M 410M 161M 2.07B 162M 159M 6.89B |
| Net Debt | 361M 311M 292M 266M 500M 34.49B 507M 3.43B 1.34B 17.28B 1.35B 1.33B 57.49B | 156M 135M 126M 115M 216M 14.92B 219M 1.48B 581M 7.48B 586M 573M 24.87B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
